Search
Sarepta Therapeutics Inc
SRPTAdd to Watchlist
17.550USD
-1.130-6.05%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.97BMarket Cap
28.16P/E TTM
More Details of Sarepta Therapeutics Inc Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Sarepta Therapeutics Inc Info
Ticker SymbolSRPT
Company nameSarepta Therapeutics Inc
IPO dateJun 04, 1997
CEOIngram (Douglas S)
Number of employees1372
Security typeOrdinary Share
Fiscal year-endJun 04
Address215 First Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16172744000
Websitehttps://www.sarepta.com/
Ticker SymbolSRPT
IPO dateJun 04, 1997
CEOIngram (Douglas S)
Company Executives of Sarepta Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.22M
+0.07%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
31.53K
+7.56%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
31.22K
-492.36%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
25.22K
+9.45%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
11.52K
-1072.63%
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Dr. Stephen L. Mayo, Ph.D.
Dr. Stephen L. Mayo, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.22M
+0.07%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
31.53K
+7.56%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
31.22K
-492.36%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
By BusinessUSD
Name
Revenue
Proportion
PMO Products
965.57M
43.92%
ELEVIDYS
898.73M
40.88%
collaboration and other
333.94M
15.19%
By RegionUSD
Name
Revenue
Proportion
United States
1.70B
77.29%
Rest of World
165.18M
7.51%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
PMO Products
965.57M
43.92%
ELEVIDYS
898.73M
40.88%
collaboration and other
333.94M
15.19%
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.89%
AQR Capital Management, LLC
7.38%
Vanguard Portfolio Management, LLC
6.29%
State Street Investment Management (US)
6.25%
Vanguard Capital Management, LLC
4.34%
Other
63.85%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.89%
AQR Capital Management, LLC
7.38%
Vanguard Portfolio Management, LLC
6.29%
State Street Investment Management (US)
6.25%
Vanguard Capital Management, LLC
4.34%
Other
63.85%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.23%
Investment Advisor/Hedge Fund
28.79%
Hedge Fund
11.54%
Research Firm
6.41%
Individual Investor
4.09%
Pension Fund
1.88%
Bank and Trust
0.73%
Family Office
0.45%
Sovereign Wealth Fund
0.35%
Other
4.54%
Institutional Shareholding
Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
1037
95.57M
90.53%
-25.27M
2025Q4
1032
91.00M
86.84%
-18.75M
2025Q3
1019
84.30M
80.53%
-21.85M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
12.56M
11.96%
+1.03M
+8.96%
Dec 31, 2025
AQR Capital Management, LLC
7.80M
7.43%
+6.39M
+454.65%
Dec 31, 2025
State Street Investment Management (US)
6.60M
6.29%
+1.29M
+24.40%
Dec 31, 2025
Two Sigma Investments, LP
4.51M
4.3%
+416.99K
+10.18%
Dec 31, 2025
Barry (Richard J)
3.21M
3.06%
+32.60K
+1.02%
May 16, 2025
Erste Asset Management GmbH
2.73M
2.6%
+43.00K
+1.60%
Dec 31, 2025
abrdn Inc.
2.25M
2.14%
+268.83K
+13.56%
Dec 31, 2025
UBS Financial Services, Inc.
2.06M
1.96%
+82.28K
+4.16%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.74%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
Invesco Biotechnology & Genome ETF
3.49%
Invesco S&P SmallCap Health Care ETF
1.44%
Global X Genomics & Biotechnology ETF
1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
1.32%
Virtus LifeSci Biotech Products ETF
1.03%
State Street SPDR S&P Biotech ETF
1.03%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Health Care Alphadex Fund
0.51%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.74%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.65%
Invesco Biotechnology & Genome ETF
Proportion3.49%
Invesco S&P SmallCap Health Care ETF
Proportion1.44%
Global X Genomics & Biotechnology ETF
Proportion1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.32%
Virtus LifeSci Biotech Products ETF
Proportion1.03%
State Street SPDR S&P Biotech ETF
Proportion1.03%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.63%
First Trust Health Care Alphadex Fund
Proportion0.51%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
